Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Observational analysis of IDO-1 expression in MEL samples assessed using an RNAscope assay.
Authors
Robert Charles Newton
Incyte Corporation, Avondale, PA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 53)
DOI
10.1200/JCO.2018.36.5_suppl.53
Abstract #
53
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
First Author: Igor Puzanov
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2020 ASCO Virtual Scientific Program
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
First Author: Jacob J. Adashek
Poster
2018 ASCO Annual Meeting
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
First Author: Daniel Olson